+31Somewhat Bullish
β steady vs. previous 30 days
30-day average of 23 articles Β· scale β100 to +100
Across 23 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Moderna news is Somewhat Bullish (+31)
on a scale from β100 to +100.
That is about the same as the previous 30 days (+33).
π Moderna raised 2026 revenue growth outlook to 15-25% driven by international performance.
β οΈ Cash outflow reached $1.56B due to litigation settlement and working capital swings.
Slightly Bullish +25
The Single Most Important Metric For Moderna Stock
AI-generated analysis
Key insights
π Moderna raised its 2026 total revenue growth outlook to 15% to 25%, up from a previous expectation of up to 10%, driven by strong international performance.
π International revenue reached $900 million in the first nine months of 2026, exceeding the company's full-year 2025 total and representing about 40% of Q3 sales.
π° The company reported an operating profit of $0.13 billion in Q3 2026, a turnaround from a $0.26 billion loss in the same quarter last year.
π Cash flow remains negative with a $1.56 billion outflow in Q3 due to a $950 million litigation settlement payment and seasonal working capital swings.
π₯ U.S. domestic COVID-19 vaccination momentum is trending flat year over year through late October, potentially limiting domestic revenue growth.
π΅ Moderna ended the quarter with $8 billion in cash and investments, supported by $2.6 billion in net proceeds from a convertible note issuance.
β οΈ Investors are concerned about Q4 seasonality which may reduce revenue as shipments between quarters shift, potentially offsetting recent third-quarter strength.
π Earnings for the full year 2026 are expected to be reported in February 2027, with a focus on whether overseas growth can sustain the raised guidance.
π The stock declined 7% during an Analyst Day session on November 12, indicating market skepticism regarding the company's current valuation relative to its financial losses.
π Bullish signals
πManagement raised its 2026 revenue growth outlook to 15% to 25%, driven by durable international partnerships in the U.K., Canada, and Australia.
πInternational revenue reached $900 million in the first nine months of 2026, surpassing the company's entire 2025 total sales.
π°The company achieved an operating profit of $0.13 billion in Q3 2026, marking a significant turnaround from a $0.26 billion loss in the same quarter last year.
π΅Moderna secured $8 billion in cash and investments at quarter-end, bolstered by $2.6 billion in net proceeds from a convertible note to fund operations.
π Risk factors
π°The company reported a twelve-month operating loss of $2.93 billion, which includes a significant $900 million litigation settlement charge.
πCash flow from operations was an outflow of $1.56 billion in Q3 2026 due to the large litigation payment and seasonal working capital swings.
π₯U.S. domestic COVID-19 vaccination momentum is trending flat year over year, limiting potential revenue growth in the home market.
β οΈRevenue seasonality poses a risk as Q4 shipments may be lower than Q3, potentially offsetting recent third-quarter strength and impacting full-year guidance.
Article
Moderna (MRNA) is facing a valuation contradiction where its stock trades at 36.8 times sales despite reporting a $2.93 billion operating loss over the last twelve months, which includes a $900 million litigation settlement charge. The company's primary growth driver has shifted to international markets, with revenue outside the U.S. reaching $900 million in the first nine months of 2026, surpassing its entire 2025 total.
Management raised its full-year 2026 revenue growth outlook to between 15% and 25%, citing durable overseas partnerships in the U.K., Canada, and Australia. While international sales now account for approximately 40% of third-quarter revenue, domestic COVID-19 vaccination momentum in the U.S. retail and long-term care channels is trending flat year over year through late October.
Financial performance remains mixed with a shift from loss to profit; Moderna recorded an operating profit of $0.13 billion in the third quarter of 2026 compared to a $0.26 billion loss a year prior, though it still posted a twelve-month operating loss on $2.52 billion in revenue. Cash flow challenges persist with an outflow of $1.56 billion from operations in Q3 due to working capital swings and the litigation payment, although the company holds $8 billion in cash and investments bolstered by recent convertible note proceeds.
Analysts are closely watching Q4 results for potential seasonality adjustments that could offset Q3 strength, with earnings expected in February 2027. The stock fell 7% following an Analyst Day on November 12, reflecting investor caution regarding the sustainability of overseas growth and the company's transition from a pandemic-focused entity to a diversified biopharma player.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Moderna (MRNA) shares surged approximately 6-7% to $241.89, significantly outpacing the broader healthcare sector and Dow Jones Industrial Average, driven by anticipation of late-stage melanoma trial data scheduled for presentation on October 24 in Madrid. The upcoming results will evaluate the combination of intismeran plus Merck's Keytruda against Keytruda alone following surgery, a program that previously demonstrated a 49% reduction in the risk of recurrence or death during Phase 2b.
The stock rally highlights Moderna's heavy dependence on its cancer pipeline to offset weak core business performance. In Q2, the company reported revenue of $145 million against a substantial net loss of $782 million, leaving it with limited financial buffer if the upcoming data disappoints. Management has confirmed manufacturing capabilities in Massachusetts are being established to support a potential launch of intismeran as its first cancer product.
Analysts and investors are closely watching whether the full data presented on October 24 will match previously announced improvements in recurrence-free and distant-metastasis-free survival, with overall survival still under evaluation. The company maintains an outlook for up to 10% revenue growth in 2026, but shares could face sharp volatility depending on whether the Phase 3 study confirms these benefits or if management's confidence holds during the investor webcast.
π Moderna stock jumped 7% to $241.89 ahead of critical melanoma trial data on October 24.
π Upcoming study shows 49% risk reduction in recurrence or death from Phase 2b data.
π Q2 revenue was $145 million with a net loss of $782 million, creating high pipeline sensitivity.
π Company is building dedicated manufacturing facilities in Massachusetts for potential intismeran launch.
β οΈ Investors face binary risk as data shortfall could pressure shares while confirmation extends rally.
π Moderna stock jumped 7% to $241.89 ahead of critical melanoma trial data expected on October 24.
π The upcoming study tests intismeran combined with Merck's Keytruda, showing a 49% risk reduction in recurrence or death from Phase 2b data.
π Moderna reported Q2 revenue of $145 million and a net loss of $782 million, creating high sensitivity to pipeline outcomes.
π The company is building dedicated manufacturing facilities in Massachusetts to support the potential launch of intismeran.
π¬ Phase 3 study results require a minimum of 18 months of follow-up, with overall survival data still pending evaluation.
π Moderna holds only 0.4% of assets in the Health Care Select Sector SPDR ETF (XLV), making its stock move distinct from larger peers like Merck.
β οΈ Investors face binary risk as a shortfall in data could pressure shares, while confirmation could extend the recent rally.
Bullish Signals
Shares surged 7% ahead of melanoma trial data.
Phase 2b showed 49% lower recurrence risk with Keytruda.
Manufacturing infrastructure established for intismeran commercial launch.
Outlook includes up to 10% revenue growth in 2026.
Risk Factors
Q2 revenue $145M vs $782M net loss.
Melanoma therapy survival data unconfirmed.
Oct 24 data shortfall risks sharp drop.
Bullish Signals
Shares surged 7% to $241.89 ahead of anticipated positive late-stage melanoma trial data presentation on October 24.
Previous Phase 2b data demonstrated a 49% reduction in the risk of recurrence or death when combining intismeran with Keytruda versus Keytruda alone.
Management confirmed manufacturing infrastructure in Massachusetts is being established to support the commercial launch of intismeran.
The company reiterated its financial outlook for up to 10% revenue growth in 2026 despite current losses.
Risk Factors
Q2 results showed only $145 million in revenue against a massive $782 million net loss, leaving the stock heavily dependent on pipeline wins.
Overall survival data for the melanoma combination therapy is still under evaluation and has not yet been confirmed.
The company faces significant binary risk where a shortfall in the October 24 data could cause sharp downward pressure on shares.
Goldman Sachs raised its price target for Moderna Inc. (MRNA) from USD 120.00 to USD 137.00 on October 15, 2026, while maintaining a Neutral rating. This adjustment reflects the company's ongoing clinical progress and market positioning within the biotechnology sector, specifically ahead of upcoming data presentations.
Moderna reported second-quarter 2026 revenue of USD 145.00 million, representing a 2.00% increase from the prior-year quarter. Despite this growth, the company recorded a net loss of USD 782.00 million, which improved by USD 43.00 million compared to the previous year, indicating a narrowing deficit as it advances its pipeline.
The company is preparing to present Phase 3 melanoma data at the European Society for Medical Oncology congress on October 24, 2026, alongside an investor webcast. These events are critical milestones that investors will monitor closely to assess the potential commercial viability of its oncology portfolio.
π Goldman Sachs raised Moderna price target to USD 137.00 on Oct 15, 2026.
π Moderna Q2 2026 revenue reached USD 145.00 million, up 2.00% year-over-year.
π° Net loss narrowed to USD 782.00 million in the second quarter of 2026.
ποΈ Investor webcast scheduled for Oct 24, 2026, to discuss upcoming clinical results.
π¬ Phase 3 melanoma data presentation planned at European Society for Medical Oncology congress.
π Goldman Sachs lifted its price target for Moderna from USD 120.00 to USD 137.00 on October 15, 2026.
π Moderna reported Q2 2026 revenue of USD 145.00 million, up 2.00% year-over-year.
π° The company's net loss narrowed to USD 782.00 million in the second quarter of 2026.
ποΈ Moderna will host an investor webcast on October 24, 2026, to discuss upcoming clinical results.
π¬ The company plans to present Phase 3 melanoma data at the European Society for Medical Oncology congress.
πΉ Moderna's market capitalization stood at USD 87.0 billion as of October 16, 2026.
π The stock traded at a P/E ratio of minus 27.32, reflecting its current loss-making status.
π Shares closed up 0.17% on the Xetra exchange at EUR 192.12 on October 19, 2026.
Bullish Signals
Goldman Sachs raised price target from $120 to $137.
Revenue grew 2% YoY to $145M in Q2 2026.
Risk Factors
Q2 2026 net loss hit USD 782 million.
Stock trades at negative P/E of -27.32.
Bullish Signals
Goldman Sachs increased its price target for Moderna from USD 120.00 to USD 137.00, signaling continued analyst interest in the company's long-term prospects.
Revenue grew by 2.00% year-over-year to USD 145.00 million in the second quarter of 2026, demonstrating top-line growth despite current profitability challenges.
Risk Factors
Moderna reported a net loss of USD 782.00 million for the second quarter of 2026, indicating the company is still operating at a significant deficit.
The stock trades at a negative P/E ratio of minus 27.32, reflecting investor caution regarding the company's current earnings trajectory and cash burn.
Analyst upgradeDrug approvalNew drug indicationAI-generated analysis
Moderna Inc. (MRNA) shares surged to a four-year high of $242.29, driven by Goldman Sachs raising its price target to $137 from $120 ahead of anticipated clinical data for its personalized cancer vaccine program. The stock jumped over 4% as investors focused on the upcoming presentation of Phase 3 melanoma data for intismeran (mRNA-4157) at the European Society for Medical Oncology Congress on October 24, which aims to demonstrate reduced disease recurrence risk.
Beyond the primary melanoma candidate, Moderna's oncology pipeline is gaining traction with early findings from its pancreatic cancer immunotherapy program adding to investor interest. Despite the positive analyst action and stock price appreciation, retail sentiment on Stocktwits shifted to 'bearish' from 'neutral,' indicating a divergence between institutional optimism regarding the drug's potential and short-term retail positioning ahead of critical trial results.
The broader market rally included other tickers like Coca-Cola and Visa, but Moderna's specific catalyst remains its oncology pipeline. The company is closely watched for evidence that its mRNA-based therapies can effectively treat cancer, a development that could significantly alter its strategic outlook beyond current revenue streams.
π Moderna stock hit four-year high of $242.29 after Goldman raised target to $137.
π¬ Investors await Phase 3 melanoma data for intismeran at ESMO Congress on Oct. 24.
π― Experimental therapy aims to reduce disease recurrence risk in melanoma patients.
π Early pancreatic cancer immunotherapy findings added interest to oncology pipeline.
π Retail sentiment flipped bearish on Stocktwits despite institutional optimism and Goldman Neutral rating.
π Moderna stock hit a four-year high of $242.29 after Goldman Sachs raised its price target to $137 from $120.
π¬ Investors are awaiting Phase 3 melanoma data for intismeran (mRNA-4157) expected at the ESMO Congress on Oct. 24.
π― The experimental therapy aims to reduce the risk of disease recurrence in melanoma patients.
π Early findings from Moderna's pancreatic cancer immunotherapy program have added to interest in its oncology pipeline.
π Retail sentiment around MRNA flipped to 'bearish' on Stocktwits despite institutional optimism.
π₯ Goldman Sachs maintained a 'Neutral' rating while lifting the target, signaling cautious but positive outlook.
Bullish Signals
Stock rose 4% to $242.29 after Goldman Sachs raised target to $137.
Personalized cancer vaccine intismeran advances toward Phase 3 data at ESMO.
Pancreatic cancer immunotherapy findings generated additional investor interest.
Risk Factors
Retail sentiment turned bearish vs. institutional optimism.
Moderna (MRNA) stock has surged 658% year-to-date, reaching a premarket price of $223.60 following positive late-stage trial data for its personalized cancer vaccine, Intismeran. Developed in partnership with Merck, the vaccine demonstrated a 49% reduction in recurrence risk when combined with Keytruda, successfully shifting investor sentiment from a post-COVID narrative to a robust oncology pipeline story.
Despite the rally, the stock trades at a significant premium to Wall Street expectations, with an analyst consensus price target of $122.67 and a separate valuation model suggesting a fair value of $134.45. The company reported a substantial loss of $782 million in the second quarter on revenue of $145 million, highlighting that current share prices assume future regulatory approvals and commercial success that have not yet been realized.
Investors face key upcoming catalysts including third-quarter earnings scheduled for November 6, which management expects to capture about 55% of second-half revenue. The company also faces specific pipeline risks, such as the recent failure of its norovirus vaccine in a Phase 3 interim analysis, while awaiting potential accelerated regulatory reviews for Intismeran if melanoma data remains positive.
Analysts maintain a mix of Hold and Sell ratings due to the high valuation multiple of 38.75x trailing sales and the gap between current pricing and projected earnings declines. While the oncology pipeline includes nine Phase 2/3 trials covering various cancers, the stock's performance now hinges on delivering on future commercial milestones rather than past pandemic-related revenue.
π Moderna stock surged 658% YTD to $223.60 on Intismeran trial success.
π Personalized vaccine cut recurrence risk 49% with Keytruda, shifting focus to oncology.
π Q2 loss hit $782M on $145M revenue despite strong stock rally.
β οΈ Shares trade at 38.75x sales vs $122.67 analyst consensus price target.
π Moderna stock surged 658% year-to-date to $223.60 driven by positive late-stage trial results for its Intismeran cancer vaccine developed with Merck.
π The personalized cancer vaccine showed a 49% reduction in recurrence risk when paired with Keytruda, transforming the company's narrative from a COVID play to an oncology-focused story.
π Moderna reported a significant loss of $782 million in Q2 on revenue of $145 million, indicating ongoing financial challenges despite the stock rally.
β οΈ The stock trades at 38.75 times trailing sales, significantly above the analyst consensus price target of $122.67 and a model fair value of $134.45.
π¬ Moderna has nine Phase 2/3 trials for Intismeran covering melanoma, lung, bladder, and kidney cancer, plus four approved products including Spikevax.
β The company's norovirus vaccine failed to meet statistical endpoints at a Phase 3 interim analysis, adding risk to its broader pipeline portfolio.
π Third-quarter earnings are scheduled for November 6, with management expecting approximately 55% of second-half revenue to be recognized in Q3.
π Management indicated that positive melanoma data could lead to an accelerated regulatory review for the Intismeran cancer vaccine.
π₯ Moderna holds four approved products and aims to have six or seven drugs by 2028 according to industry panelists.
π Shares remain 31% below their five-year high of $324.21, suggesting the current price may still be below historical peaks despite recent gains.
Bullish Signals
Intismeran cut recurrence risk 49% with Keytruda in trial.
Shifted narrative to oncology success after positive clinical data.
Projected six to seven drugs by 2028 for growth.
Positive melanoma data may accelerate regulatory review.
Moderna's personalized cancer vaccine, Intismeran, showed a 49% reduction in recurrence risk when combined with Keytruda in its first late-stage trial.
The company successfully transformed its market narrative from a post-COVID play to a promising oncology pipeline story following positive clinical data.
Investors anticipate Moderna could have six or seven drugs by 2028, indicating strong potential for future product diversification and revenue growth.
Positive melanoma data for Intismeran could trigger an accelerated regulatory review, potentially speeding up market entry for the cancer vaccine.
Risk Factors
Moderna lost $782 million in Q2 on revenue of $145 million, reflecting significant ongoing financial losses despite recent stock price gains.
The stock trades at a premium valuation of 38.75 times trailing sales, which is well above the analyst consensus target of $122.67 and model fair value of $134.45.
The company's norovirus vaccine failed to meet statistical endpoints at a Phase 3 interim analysis, highlighting risks within its broader pipeline.
Analyst consensus ratings are dominated by Hold and Sell recommendations due to the high current price relative to projected earnings declines.
Company updateEarnings reportAI-generated analysis
The article compares Moderna (MRNA) and Vertex Pharmaceuticals (VRTX), noting that while Moderna pioneered mRNA vaccines, it faces significant financial headwinds as demand for its COVID-19 products tapers. In fiscal year 2025, Moderna's revenue declined by approximately 39.2% to nearly $1.9 billion, resulting in a net loss of roughly $2.8 billion and negative free cash flow of $2.1 billion.
In contrast, Vertex Pharmaceuticals is highlighted as a profitable leader in cystic fibrosis treatments with revenue growing 9.6% to $12.1 billion in FY 2025. The company posted net income of nearly $4.0 billion and generated $3.2 billion in free cash flow, maintaining a strong balance sheet with low debt relative to equity.
Moderna is described as playing a longer game to prove its platform works across various diseases, but it currently struggles with intense competition from giants like Pfizer and Sanofi, plus legal risks including a $950 million settlement. Vertex faces revenue concentration risk in cystic fibrosis and clinical development risks, such as the discontinuation of its VX-264 diabetes program, but is viewed as delivering immediate value.
The author concludes that Vertex is the preferred choice for investors seeking current profitability and cash generation, whereas Moderna represents a higher-risk, longer-term opportunity dependent on successfully transitioning its portfolio beyond infectious disease vaccines.
π Moderna FY 2025 revenue dropped 39.2% to $1.9 billion amid COVID demand taper.
πΈ Moderna recorded a net loss of $2.8 billion and negative free cash flow in FY 2025.
βοΈ Moderna faces intense competition from Pfizer, Sanofi, and GSK in the vaccine market.
β οΈ Moderna is involved in a $950 million legal settlement with Arbutus Biopharma over IP.
π Moderna reported a net loss of $1.34 billion in Q1 2026 during financial transition.
π Moderna's FY 2025 revenue dropped roughly 39.2% to nearly $1.9 billion as demand for COVID-19 products tapered.
πΈ Moderna reported a net loss of approximately $2.8 billion in FY 2025 with negative free cash flow of nearly $2.1 billion.
π Vertex Pharmaceuticals achieved revenue growth of 9.6% to reach close to $12.1 billion in FY 2025.
π° Vertex posted net income of nearly $4.0 billion and generated $3.2 billion in free cash flow during FY 2025.
βοΈ Moderna faces intense competition from established giants like Pfizer, Sanofi, and GSK in the vaccine market.
β οΈ Moderna is involved in a significant legal risk involving a $950 million settlement with Arbutus Biopharma regarding intellectual property.
π₯ Vertex carries revenue concentration risk as its business is heavily dependent on its cystic fibrosis portfolio.
𧬠Vertex faces clinical development risks illustrated by the recent discontinuation of its VX-264 program for diabetes.
π Moderna reported a significant net loss of $1.34 billion in Q1 2026, continuing its financial transition challenges.
π Vertex management raised its full-year outlook in Q2 2026 while expanding its pipeline beyond cystic fibrosis.
Bullish Signals
Global manufacturing footprint supports versatile platform technology.
Partnered with Recordati to advance new therapeutics.
Risk Factors
FY 2025 revenue declined 39.2% due to tapering COVID-19 demand.
FY 2025 net loss reached $2.8 billion with -145.2% margin.
FY 2025 negative free cash flow was nearly $2.1 billion.
Faces intense competition from Pfizer, Sanofi, and GSK in vaccines.
Settled $950M IP dispute with Arbutus Biopharma legal risk.
Bullish Signals
Moderna maintains a global manufacturing footprint and operates in the biotech landscape with a platform technology capable of being retooled for almost any disease.
The company recently partnered with Recordati to advance new therapeutics, indicating ongoing strategic collaboration efforts.
Risk Factors
Moderna's FY 2025 revenue declined by roughly 39.2% compared to the prior year due to tapering demand for COVID-19 products.
The company reported a net loss of approximately $2.8 billion in FY 2025, resulting in a negative net margin of 145.2%.
Moderna experienced negative free cash flow of nearly $2.1 billion during FY 2025 after paying for capital expenditures.
The company faces intense competition from established giants like Pfizer, Sanofi, and GSK in the vaccine market.
Moderna is involved in a prominent legal risk including a $950 million settlement with Arbutus Biopharma regarding intellectual property.
The company reported a significant net loss of $1.34 billion in Q1 2026, highlighting continued financial pressure.
Company updateRegulatory submissionAI-generated analysis
Moderna stock surged 14.2% on October 9 following reports of a new NIH-backed initiative aimed at accelerating cancer vaccine development. The Therapeutic Cancer Vaccines Initiative is described as a $200 million public-private effort to coordinate clinical trials and research infrastructure, highlighting the potential for mRNA technology in personalized cancer treatments beyond infectious diseases.
Despite the market enthusiasm, analysts note that the initiative's funding does not constitute direct revenue awarded to Moderna, and no immediate financial benefit has been confirmed. Consequently, investors are pricing in significant future growth based on the stock's rally, which pushed its valuation to approximately 41.3 times next-twelve-month sales, near its five-year high.
The article highlights a critical upcoming catalyst for the company: a Phase 3 melanoma presentation scheduled for October 24 with partner Merck at the ESMO Congress. Strong results from this trial could support expectations for future growth, while disappointing data could challenge the current optimism reflected in Moderna's share price given its premium valuation relative to historical averages.
Wall Street consensus estimates project Moderna's revenue reaching $3.39 billion by fiscal 2028, representing approximately 75% growth from 2025 levels but still less than half of its 2023 revenue. This forecast suggests a recovery path, yet the contribution from the oncology pipeline remains uncertain and is the primary variable determining whether the stock can justify its current premium multiple.
π Moderna stock surged 14.2% on October 9 following NIH cancer vaccine initiative reports.
π° The $200 million public-private effort lacks confirmed direct revenue awards for Moderna.
π Revenue projected to hit $3.39 billion by fiscal 2028, up ~75% from 2025.
π Shares trade at 41.3x next-twelve-month sales, near a five-year high of 42.6x.
π¬ Key catalyst: October 24 Phase 3 melanoma presentation with Merck at ESMO Congress.
π Moderna stock surged 14.2% on October 9 after reports of an NIH-backed initiative to accelerate cancer vaccine development.
π° The Therapeutic Cancer Vaccines Initiative is a $200 million public-private effort, though no direct revenue award has been confirmed for Moderna.
π Analysts project Moderna's revenue will reach $3.39 billion by fiscal 2028, representing approximately 75% growth from 2025 levels.
π Moderna currently trades at approximately 41.3 times next-twelve-month sales, near its five-year high of 42.6x.
π¬ A key upcoming catalyst is the October 24 Phase 3 melanoma presentation with Merck at the ESMO Congress.
β οΈ Investors are pricing in significant future growth before any confirmed financial benefit from the NIH initiative.
ποΈ Moderna was added to the Nasdaq-100 index, contributing to broader enthusiasm for vaccine developers alongside Novavax.
Bullish Signals
Stock surged 14.2% on Oct 9 amid cancer vaccine initiative.
Added to Nasdaq-100 index, boosting investor enthusiasm.
Revenue expected $3.39B by 2028, up 75% from 2025.
Risk Factors
NIH funding not awarded directly to Moderna.
Trades at 41.3x sales premium with little room for error.
Projected 2028 revenue less than half of 2023 level.
Bullish Signals
Moderna stock surged 14.2% on October 9 following reports of an NIH-backed initiative to accelerate cancer vaccine development.
The company was added to the Nasdaq-100 index, reflecting renewed investor enthusiasm for its mRNA technology platform.
Analysts expect Moderna's revenue to reach $3.39 billion by fiscal 2028, representing approximately 75% growth from 2025 levels.
Risk Factors
The NIH initiative's funding is not awarded directly to Moderna, and no immediate financial benefit has been confirmed.
Moderna trades at a premium valuation of approximately 41.3 times next-twelve-month sales, leaving little room for disappointment if the oncology pipeline fails.
Projected revenue by 2028 is less than half of the company's 2023 level, suggesting a significant recovery path with uncertain contributions from the cancer vaccine pipeline.
Moderna (NASDAQ:MRNA) shares surged approximately 14.2% to close at $225.00 on October 9, 2026, reaching a multi-year high driven by two distinct catalysts. The primary driver was the company's re-inclusion into the Nasdaq-100 Index (NDX), which mandates automatic buying by over 200 investment products managing more than $800 billion in assets. This mechanical demand lifted the stock from a prior close of $197, marking a significant technical milestone after Moderna had been dropped from the index in December 2024 due to its post-pandemic valuation decline.
The second major catalyst was a New York Times report detailing a proposed national initiative by the National Institutes of Health (NIH) to accelerate personalized cancer vaccine development. This public-private partnership, modeled after the successful COVID-19 vaccine rollout, focuses on pancreatic, liver, and colorectal cancers with an expected launch in December. The report positioned Moderna as a central beneficiary due to its ongoing collaboration with Merck (NYSE:MRK) on mRNA tumor therapies, reinforcing the market's view of the company's strategic position in the next wave of cancer treatment.
Fundamentally, the rally is underpinned by recent clinical successes in Moderna and Merck's Phase 3 INTerpath-001 trial for intismeran autogene (mRNA-4157). The combination therapy met its primary goal of delaying recurrence in patients with resected, high-risk melanoma and achieved a key secondary endpoint regarding distant metastasis-free survival. This represents the first positive late-stage readout for an mRNA tumor therapy, validating the technology's potential despite previous market skepticism. Full data from ongoing trials in lung, kidney, and bladder cancers are scheduled for presentation at the European Society for Medical Oncology (ESMO) congress in Madrid on October 24.
Despite the strong performance, which includes a year-to-date gain of over 600% from a low near $22, analysts warn that the stock may be overvalued relative to its current pipeline status. Citi analyst Geoff Meacham noted that under current assumptions, Moderna would require approximately $26 billion in annual cancer treatment sales to justify a price near $200, a high bar for an unapproved product. Investors are advised to separate the mechanical index-driven demand from fundamental shifts and await the October 24 data presentation to determine if the rally represents a durable breakout or a peak driven by headlines.
π Moderna shares surged 14.2% to $225 after Nasdaq-100 re-inclusion.
ποΈ Over 200 funds managing $800B must buy MRNA automatically.
π¬ Phase 3 melanoma trial met primary goal for intismeran therapy.
π Lung, kidney, and bladder cancer data due October 24 at ESMO.
β οΈ Citi warns shares may be overvalued needing $26B annual sales.
π Moderna shares jumped 14.2% to $225.00, hitting a multi-year high following re-inclusion into the Nasdaq-100 Index and positive news regarding national cancer vaccine initiatives.
ποΈ The company's return to the Nasdaq-100 mandates automatic buying by over 200 index-tracking funds managing more than $800 billion in assets, creating immediate mechanical demand.
π¬ Moderna and Merck reported that their Phase 3 trial for intismeran autogene met its primary goal of delaying recurrence in high-risk melanoma patients, marking the first positive late-stage readout for an mRNA tumor therapy.
π Full clinical data for lung, kidney, and bladder cancer trials are scheduled for presentation at the ESMO congress in Madrid on October 24, serving as the next major catalyst.
π€ The NIH announced a planned national push for personalized cancer vaccines modeled after the COVID-19 success, with Moderna positioned as a prime beneficiary of this public-private partnership.
β οΈ Citi analyst Geoff Meacham suggests Moderna shares may be overvalued, estimating the company needs roughly $26 billion in annual sales to justify a price near $200 given current pipeline status.
π The stock has rallied more than 600% year-to-date from a low of $22, leaving little room for disappointment as index-driven flows may reverse once rebalancing concludes.
π Investors are advised to separate mechanical index buying from fundamental shifts and monitor the October 24 data presentation to assess the durability of the breakout.
Bullish Signals
Shares surged 14.2% to $225.00 after Nasdaq-100 re-inclusion.
Merck collaboration met primary goal for melanoma recurrence delay.
Positioned to benefit from NIH national cancer vaccine initiative.
mRNA therapy validated by effective tumor recurrence delay results.
Lung, kidney, and bladder cancer trial data coming Oct 24.
Risk Factors
Shares overvalued after 600% YTD run; Citi needs $26B sales to justify.
Rally driven by index rebalancing; price support may weaken soon.
Bullish Signals
Moderna shares surged 14.2% to $225.00, reaching a multi-year high driven by re-inclusion into the Nasdaq-100 Index which triggers mandatory buying from over $800 billion in assets.
The company's collaboration with Merck achieved a historic milestone as their Phase 3 trial for intismeran autogene met its primary goal of delaying recurrence in high-risk melanoma patients.
Moderna is positioned as a central beneficiary of the NIH's new national cancer vaccine initiative, which aims to replicate the success of the COVID-19 vaccine rollout for pancreatic and other cancers.
The mRNA tumor therapy approach has proven effective in delaying recurrence and improving distant metastasis-free survival, validating the technology after years of market skepticism.
Full data from trials in lung, kidney, and bladder cancers are set to be presented at ESMO on October 24, providing further evidence of the platform's versatility.
Risk Factors
Analysts warn that Moderna shares may be overvalued after a 600% year-to-date run, with Citi estimating the company needs $26 billion in annual sales to justify current pricing.
The recent rally is partially driven by mechanical index rebalancing rather than fundamental changes, meaning price support could weaken once the mandatory buying period concludes.
Moderna (NASDAQ:MRNA) shares surged more than 14% on Friday following reports of a major new cancer research initiative. The National Institutes of Health plans to launch a campaign in December to fast-track cancer treatment research, aiming to replicate the success seen with early-stage Covid-19 vaccine development.
This public-private partnership will unite researchers and resources from various healthcare companies and nonprofits to accelerate scientific discoveries. Initial efforts will focus on pancreatic, liver, colorectal cancers, and pediatric tumors, leveraging advances in AI and mRNA technology to design personalized immune system treatments.
The initiative aligns with recent positive clinical data where Moderna's co-developed therapy, intismeran, combined with Merck's Keytruda, extended progression-free survival for high-risk melanoma patients. These developments are expected to accelerate Moderna's development timelines, potentially enabling faster delivery of new therapies and profits to shareholders.
Despite the bullish news driving the stock price higher, The Motley Fool notes that Moderna was not included in their current list of top 10 stocks for investors, citing a specific analyst team recommendation rather than general market consensus.
π Moderna shares jumped 14% on NIH cancer research initiative news.
π¬ New partnership will use mRNA tech for pancreatic and liver cancers.
π Co-developed therapy intismeran extended progression-free survival in high-risk melanoma.
β‘ Positive results expected to accelerate Moderna's development timelines.
π Motley Fool excluded Moderna from top 10 long-term growth list.
π Moderna shares jumped over 14% on Friday after reports of a major new NIH cancer research initiative.
π¬ The NIH plans to fast-track cancer treatment research in December, aiming to replicate early pandemic vaccine success.
π€ The new public-private partnership will combine resources from healthcare companies and nonprofits to accelerate discoveries.
π― Initial research focus includes pancreatic, liver, colorectal cancers, and pediatric tumors using AI and mRNA tech.
π Moderna's co-developed therapy intismeran showed success in extending progression-free survival for high-risk melanoma patients.
β‘ Positive clinical results are expected to accelerate Moderna's development timelines and potential profit delivery.
π The Motley Fool Stock Advisor recently excluded Moderna from their top 10 stocks list for long-term growth.
Bullish Signals
Shares jumped 14% on major cancer research initiative reports.
NIH plans fast-track cancer treatment research in December.
Public-private partnership will accelerate scientific discoveries.
AI and mRNA tech enable tailored patient treatments.
Co-developed therapy with Merck increased time before cancer return.
New initiative could accelerate development timelines and profits.
Bullish Signals
Shares of Moderna jumped more than 14% on Friday following reports of a major new cancer research initiative.
The NIH plans to fast-track cancer treatment research in December, aiming to replicate the success of early-stage Covid-19 vaccine development.
A new public-private partnership will unite researchers and resources from various healthcare companies to accelerate scientific discoveries.
Advances in AI and mRNA technology are enabling doctors to design treatments tailored to each patient's immune system.
Moderna and Merck announced that their co-developed investigational mRNA-based therapy, intismeran, increased the time before cancer returned or spread in patients with high-risk melanoma.
Encouraging clinical trial results are prompting healthcare leaders to devote more resources to cancer research.
The new initiative could help accelerate Moderna's development timelines, potentially enabling the biotech to deliver new therapies to patients and profits to shareholders faster than previously expected.
Moderna Inc. (MRNA) shares surged 5% to $208 following its inclusion in the NASDAQ 100 index, a move that triggered mandatory buying by index funds regardless of valuation. This mechanical inflow pushed the biotech firm's stock significantly higher than peers Pfizer and BioNTech on the day, though analysts note the rally may face headwinds once these passive purchases conclude.
The company's re-rating is fundamentally driven by its successful transition from a COVID-19 vaccine manufacturer to a growth biotech focused on oncology. Specifically, Moderna's personalized cancer therapy met its primary endpoint for recurrence-free survival in a late-stage study involving high-risk melanoma patients, validating the expansion of its messenger RNA platform beyond vaccines.
While the index addition provided immediate liquidity support, the long-term sustainability of the stock depends on whether operational results and pipeline progress can maintain momentum after the rebalancing window closes. Investors are now watching for further oncology data that signals movement toward product revenue to justify the company's new growth status.
π Moderna shares jumped 5% to $208 after joining NASDAQ 100.
𧬠Oncology trial met primary endpoint in high-risk melanoma patients.
π Company repriced from COVID vaccine maker to growth biotech.
β οΈ Mechanical buying support may fade once index funds complete purchases.
π Stock now trades as oncology-focused growth biotech distinct from peers.
π Moderna shares jumped 5% to $208 immediately after joining the NASDAQ 100, forcing index funds to buy shares mechanically.
𧬠The stock rally is anchored by a late-stage oncology trial success where personalized cancer therapy met its primary endpoint in high-risk melanoma patients.
π Moderna has successfully repriced from a COVID-19 vaccine maker into a growth biotech with an oncology pipeline, standing alone among peers for this specific re-rating.
β οΈ Analysts warn that the mechanical buying support may fade once index funds complete their purchases, leaving the stock to rely on organic pipeline progress.
π The company now trades as a growth biotech with an oncology focus, distinct from vaccine peers Pfizer and BioNTech which are moving on different drivers.
Bullish Signals
Shares surged 5% to $208 after NASDAQ 100 inclusion.
Cancer therapy met primary endpoint in late-stage melanoma study.
Transitioned to growth biotech with validated oncology pipeline.
Risk Factors
Rally driven by passive rebalancing, not fundamentals.
Gains may fade once mechanical buying concludes.
Bullish Signals
Moderna shares surged 5% to $208 following its inclusion in the NASDAQ 100, generating significant mechanical buying pressure from index funds.
The company achieved a major clinical milestone as its personalized cancer therapy met the primary endpoint of recurrence-free survival in a late-stage study for high-risk melanoma patients.
Moderna has successfully transitioned its market identity from a COVID-19 vaccine manufacturer to a growth biotech with a validated oncology pipeline, justifying its re-rating into a large-cap growth index.
Risk Factors
The current stock rally is partially driven by passive index rebalancing rather than fresh fundamental analysis, creating uncertainty about whether gains will hold once mechanical buying concludes.
Investors face the risk that future stock performance will depend entirely on pipeline updates moving closer to product revenue, as the immediate support from index inclusion is temporary.
Moderna (MRNA) shares rose 7% on Monday following a global market rally in biodefense and vaccine stocks triggered by the unexplained death of a Russian lab worker. While the incident sparked speculation about federal contracts for plague preparedness, the World Health Organization assessed the public risk as low, and Russian authorities declared the regional situation stable.
Unlike peers with direct smallpox or anthrax portfolios, Moderna does not currently hold commercial vaccines targeting plague. However, the company's mRNA technology platform remains a central asset in emerging-pathogen trades, allowing it to benefit from broader outbreak sentiment even without specific plague products. The rally was driven largely by retail investors speculating on potential government purchases and heightened preparedness needs.
Despite the stock price surge, investor sentiment on social platforms remained neutral for MRNA despite high message volume, contrasting with 'extremely bullish' sentiment seen in Novavax and Emergent BioSolutions. The article notes that Moderna markets COVID-19 vaccines like Spikevax and the RSV vaccine mRESVIA, leveraging its established mRNA technology rather than relying on a specific plague treatment opportunity.
π Moderna shares rose 7% amid biodefense rally following Russian lab worker death.
π¦ Retail speculation on federal contracts drove stock despite WHO's low public risk assessment.
π Moderna leverages mRNA platform rather than specific plague vaccines like peers.
π Investor sentiment stayed neutral on social platforms despite 589% year-to-date gain.
π Company markets COVID-19 and RSV vaccines but does not target plague commercially.
π Moderna (MRNA) shares climbed 7% amid a broader rally in biodefense stocks following news of a Russian lab worker's death.
π¦ The stock move was driven by retail speculation on federal contracts and preparedness, though the WHO assessed public risk as low.
π Unlike peers with direct plague portfolios, Moderna benefits from its mRNA technology platform rather than specific plague vaccines.
π Investor sentiment for MRNA remained neutral on social platforms despite high message volume and a 589% year-to-date gain.
π Moderna markets COVID-19 and RSV vaccines but does not currently target plague with its commercial portfolio.
Bullish Signals
Shares rose 7% amid biodefense rally.
Benefits from retail speculation on government contracts.
mRNA platform key for emerging-pathogen trades.
Risk Factors
Lacks plague vaccine portfolio limiting relevance vs peers.
Neutral investor sentiment shows less retail conviction.
Bullish Signals
MRNA shares rose 7% as part of a broad rally in biodefense stocks triggered by geopolitical health concerns.
The company benefits from strong retail speculation regarding potential government contracts for emerging pathogen preparedness.
Moderna's established mRNA technology platform positions it as a key player in emerging-pathogen trades regardless of specific disease targets.
Risk Factors
MRNA lacks a direct commercial vaccine portfolio targeting plague, limiting its specific relevance to the immediate catalyst compared to peers like Emergent BioSolutions.
Investor sentiment for MRNA remained neutral on social platforms despite high message volume, indicating less retail conviction than seen in Novavax or Emergent.
Moderna Inc. (NASDAQ:MRNA) shares surged approximately 175% in the third quarter, driven by a landmark Phase 3 clinical trial success for its combined therapy candidate targeting melanoma. The combination of Moderna's Intismeran Autogene and Merck's Keytruda met both primary and secondary endpoints regarding recurrence-free and distant metastasis-free survival, marking the first positive readout for an mRNA-based cancer treatment combined with individualized neoantigen therapy to demonstrate clinically meaningful improvement over Keytruda alone.
The successful trial results point to significant revenue growth prospects for Moderna in the coming years, leveraging the huge addressable market for melanoma treatments. Melanoma remains a critical focus area, with global diagnoses reaching 330,000 cases in 2022 and expected case increases projected for the current year. This breakthrough validates the efficacy of mRNA technology in oncology beyond infectious diseases.
In addition to its cancer pipeline, Moderna secured FDA approval for updated Spikevax and mNEXSPIKE COVID-19 vaccine formulas intended for the 2026 to 2027 seasons. The new formulations expand eligibility to include children aged 6 months to 64 years with underlying conditions and all adults aged 65 and older, addressing high-risk demographics. Concurrently, Moderna is set to join the Nasdaq-100 index on October 9, replacing Warner Bros. Discovery, which may trigger further portfolio rebalancing by institutional investors.
π Moderna stock surged 174.98% after melanoma combo therapy hit Phase 3 endpoints.
π° Strong trial results signal significant near-term revenue growth from the large melanoma market.
π Moderna joins Nasdaq-100 index on October 9, potentially driving further price appreciation.
π FDA approved updated Spikevax and mNEXSPIKE formulas for 2026-2027 seasons.
πΆ New vaccine approvals expand eligibility to children aged 6 months and adults over 65.
π Moderna stock jumped 174.98% in Q3 following a successful Phase 3 trial for its melanoma combination therapy.
β The Intismeran Autogene and Merck Keytruda combo met primary and secondary endpoints for recurrence-free and distant metastasis-free survival.
π¬ This marks the first positive Phase 3 readout for an mRNA-based cancer treatment combined with individualized neoantigen therapy.
π° Successful trials indicate strong revenue growth prospects for Moderna in the near future due to the large melanoma market.
π Moderna is scheduled to join the Nasdaq-100 index on Friday, October 9, potentially driving further stock price appreciation.
π The FDA approved updated Spikevax and mNEXSPIKE COVID-19 vaccine formulas for the 2026-2027 seasons.
πΆ New COVID-19 vaccine approvals expand eligibility to children aged 6 months to 64 with underlying conditions and all adults over 65.
π¦ Moderna's mRNA technology has proven effective in both oncology and infectious disease prevention pipelines.
Bullish Signals
Stock surged 174.98% after Phase 3 melanoma trial success.
First positive Phase 3 readout for mRNA cancer combo therapy.
FDA approved updated Spikevax formulas for 2026-2027 seasons.
Melanoma trial results signal significant future revenue growth.
Joining Nasdaq-100 on Oct 9 may trigger rebalancing.
Bullish Signals
Moderna stock surged 174.98% in Q3 following a landmark Phase 3 clinical trial success for its melanoma combination therapy.
The company achieved the first positive readout from a Phase 3 trial combining mRNA-based cancer treatment with individualized neoantigen therapy, demonstrating clinically meaningful improvement over Keytruda alone.
FDA approval was granted for updated Spikevax and mNEXSPIKE COVID-19 vaccine formulas for the 2026 to 2027 seasons, expanding eligibility to younger children and high-risk adults.
The successful melanoma trial results point to significant revenue growth prospects for Moderna in the coming years due to the huge addressable market for skin cancer treatments.
Moderna is set to join the Nasdaq-100 index on October 9, which may trigger portfolio rebalancing by institutional investors and funds mirroring the index composition.
Moderna Inc. stock gained 0.57 percent to close at USD 190.01 on October 2, 2026, as the company prepares for its inclusion in the Nasdaq-100 index effective October 9, 2026. This benchmark status is expected to drive inflows from index-tracking funds, placing Moderna in a major portfolio tracked by over 200 investment products and replacing Warner Bros. Discovery in the index.
The biotechnology company reported second-quarter 2026 revenue of USD 145 million, representing a 2.1 percent year-over-year increase from USD 142 million. Concurrently, its GAAP net loss narrowed to USD 782 million from USD 825 million in the prior year, with the loss per share decreasing to USD 1.97 from USD 2.13.
Despite the positive index news and revenue growth, analyst sentiment remains mixed with a Hold consensus from 25 analysts. Citi recently downgraded Moderna to Sell while raising its price target to USD 80.00, contrasting with the broader market optimism surrounding the index inclusion and the company's oncology pipeline developments.
π Moderna stock rose 0.57% to $190.01 ahead of Nasdaq-100 inclusion.
π Q2 2026 revenue grew 2.1% YoY to $145 million with narrowed loss.
π Citi downgraded Moderna to Sell with $80 price target despite index news.
π― Company reiterated 2026 revenue growth outlook of up to 10%.
π Investor event scheduled for October 24 linked to ESMO Congress data.
π Moderna stock gained 0.57 percent to close at USD 190.01 on October 2, 2026, ahead of its Nasdaq-100 inclusion scheduled for October 9.
π Q2 2026 revenue rose 2.1 percent year-over-year to USD 145 million, while GAAP net loss narrowed to USD 782 million.
π The Nasdaq-100 entry replaces Warner Bros. Discovery and affects over 200 investment products tracking the major benchmark index.
π Citi downgraded Moderna from Neutral to Sell on September 30, raising its price target to USD 80.00 despite the positive index news.
π― The company reiterated a 2026 revenue-growth outlook of up to 10 percent while continuing investment in vaccines and oncology pipelines.
π Moderna will host an investor event on October 24, 2026, linked to data presented at the ESMO Congress.
Bullish Signals
Stock gained 0.57% ahead of Nasdaq-100 inclusion on Oct 9, 2026.
Q2 2026 revenue rose 2.1% YoY to USD 145 million.
GAAP net loss narrowed to USD 782 million from USD 825 million.
Risk Factors
Citi downgraded to Sell on Sept 30, 2026 due to high valuation.
Bullish Signals
Moderna stock gained 0.57 percent as it prepares for Nasdaq-100 inclusion effective October 9, 2026, which places the company in a major benchmark tracked by over 200 investment products.
Q2 2026 revenue increased 2.1 percent year-over-year to USD 145 million, demonstrating continued top-line growth despite market headwinds.
GAAP net loss narrowed significantly to USD 782 million from USD 825 million in the prior year, with loss per share dropping to USD 1.97.
Risk Factors
Citi downgraded Moderna from Neutral to Sell on September 30, 2026, citing a contrast between index inclusion optimism and concerns over current valuation.
Moderna Inc. (MRNA) was added to the Nasdaq-100 index effective October 9, 2026, replacing Warner Bros. Discovery. This inclusion is expected to drive significant passive capital inflows into the stock as funds tracking the benchmark adjust their portfolios. The move marks a structural shift in the company's market classification, elevating its profile among large-cap non-financial technology and healthcare leaders.
Despite the index inclusion, analyst sentiment remains mixed following a downgrade by Citigroup on September 30, 2026. Citi downgraded Moderna from Hold to Sell while simultaneously raising its price target to USD 80 from USD 60. This divergence highlights a disconnect between the market's current valuation of approximately USD 190 per share and the analyst's fundamental outlook, which suggests the stock is overvalued relative to its projected performance.
Financially, Moderna reported Q2 2026 revenue of USD 145 million, representing a modest 2% year-over-year increase. The company posted an adjusted loss per share of USD 1.97 and a GAAP net loss of USD 782 million for the quarter. Investors are closely watching upcoming clinical data for autogene, its personalized cancer vaccine developed with Merck, which is scheduled to be presented at the European Society for Medical Oncology Congress on October 24, 2026.
π Moderna joins Nasdaq-100 index Oct 9, 2026, replacing Warner Bros. Discovery.
π Citi downgrades MRNA to Sell with USD 80 price target on Sept 30, 2026.
π° Stock closed at USD 190.01, trading 57.9% above Citi's new target.
π Q2 2026 revenue rose 2% YoY to USD 145M amid USD 782M GAAP loss.
π¬ Investors await Oct 24, 2026 clinical data for autogene cancer vaccine with Merck.
π Moderna joins the Nasdaq-100 index on October 9, 2026, replacing Warner Bros. Discovery and triggering expected passive buying from index-tracking funds.
π Citigroup downgraded Moderna to a Sell rating on September 30, 2026, while raising its price target to USD 80 from USD 60.
π° The stock closed at USD 190.01 on October 2, 2026, trading 57.9% above Citi's new price target and near its 52-week high of USD 208.90.
π Q2 2026 revenue reached USD 145 million, a 2% increase year-over-year, while the company reported a GAAP net loss of USD 782 million.
π¬ Investors await clinical data for autogene, Moderna's personalized cancer vaccine in development with Merck, to be presented on October 24, 2026.
Bullish Signals
Added to Nasdaq-100 on Oct 9, 2026.
Q2 2026 revenue grew 2% YoY to $145M.
Risk Factors
Citi downgraded to Sell on Sept 30, 2026 due to high valuation.
Stock trades at $190.01, 57.9% above Citi's $80 target.
Q2 2026 adjusted loss was $1.97/share and GAAP loss $782M.
Bullish Signals
Moderna was added to the Nasdaq-100 index effective October 9, 2026, which will likely trigger substantial passive capital inflows from funds tracking the benchmark.
The company reported Q2 2026 revenue of USD 145 million, marking a 2% year-over-year growth despite ongoing operational losses.
Risk Factors
Citigroup downgraded Moderna to a Sell rating on September 30, 2026, citing that the current market valuation is disconnected from fundamental value.
The stock trades at USD 190.01, which is 57.9% above Citi's new price target of USD 80, indicating a significant bearish divergence between market price and analyst consensus.
Moderna reported an adjusted loss per share of USD 1.97 and a GAAP net loss of USD 782 million for the second quarter of 2026.
Moderna (MRNA) shares rallied 2.2% in pre-market trading on Friday, reaching $193.15, driven by the company's inclusion in the Nasdaq-100 Index effective October 9. This index rebalancing replaces Warner Bros. Discovery, which is being absorbed into Paramount Skydance following a judge-approved settlement expected to close on October 6. The shift triggers mandatory buying from funds tracking the $800 billion index, creating significant upward pressure on Moderna's stock price.
The rally reflects an extraordinary year for the biotech firm, with shares surging approximately 553% since January to a market value near $75.4 billion. Much of this momentum stems from positive Phase 3 interim results for intismeran autogene, a personalized melanoma vaccine developed in partnership with Merck, which drove a roughly 222% gain since those reports. Moderna is currently trading close to its 52-week high of $208.90, marking a dramatic recovery from years of decline following the pandemic-era vaccine boom.
Despite the bullish market reaction, analyst sentiment remains divided regarding the stock's valuation. Citi analyst Geoff Meacham downgraded Moderna to Sell from Neutral, citing unrealistic sales expectations required to justify the current price near $200. While the average Wall Street price target sits at $110.44, representing a 42% discount to current levels, investors are now awaiting new data presentation at the ESMO conference on October 24, which could serve as the next major catalyst for the stock.
π Moderna shares rose 2.2% to $193.15 after Nasdaq-100 inclusion.
π Stock surged 553% since January driven by melanoma vaccine Phase 3 results.
π Citi downgraded to Sell citing need for $13B annual oncology sales.
π Appointed new COO Juan Andres to scale manufacturing operations.
ποΈ Investors await ESMO conference data on October 24 as catalyst.
π Moderna shares climbed 2.2% in pre-market trading to $193.15 following confirmation of its inclusion in the Nasdaq-100 Index before markets open on October 9.
π The index rebalancing replaces Warner Bros. Discovery, triggering mandatory buying from over $800 billion in assets tied to the benchmark index.
π Moderna stock has surged approximately 553% since January, reaching a market value near $75.4 billion driven by positive Phase 3 results for its melanoma vaccine intismeran autogene.
π Citi analyst Geoff Meacham downgraded Moderna to Sell from Neutral, arguing the current price near $200 requires nearly $13 billion in yearly oncology sales to justify.
π€ The company's positive stock performance is largely attributed to a 222% gain since reporting interim results for its personalized melanoma vaccine developed alongside Merck.
π Moderna appointed Juan Andres as the new Chief Operating Officer to help scale manufacturing operations as its oncology pipeline expands.
π Wall Street consensus remains split with an average price target of $110.44, which is 42% below the current trading price.
ποΈ Investors are anticipating new data presentation at the ESMO conference on October 24, which could act as a future catalyst for the stock.
Bullish Signals
Shares rallied 2.2% pre-market to $193.15 after Nasdaq-100 inclusion.
Risk Factors
Citi downgraded to Sell citing unrealistic oncology sales expectations near $200.
Analysts deem current valuation unrealistic given cancer business forecasts.
Average price target of $110.44 is 42% below current stock.
Bullish Signals
Moderna shares rallied 2.2% in pre-market trading to $193.15 following its official inclusion in the Nasdaq-100 Index effective October 9.
The index rebalancing creates significant buying pressure as funds tracking the $800 billion Nasdaq-100 must purchase shares to maintain their benchmark allocations.
Moderna stock has gained approximately 553% since January, reaching a market value near $75.4 billion in an extraordinary year for the company.
Positive Phase 3 interim results for intismeran autogene, a personalized melanoma vaccine developed with Merck, drove a roughly 222% gain in shares since those reports were released.
The stock is currently trading close to its 52-week high of $208.90, marking a dramatic turnaround from years of decline after the pandemic-era vaccine boom faded.
Risk Factors
Citi analyst Geoff Meacham downgraded Moderna to Sell from Neutral, stating that the current share price near $200 implies nearly $13 billion in yearly oncology sales.
Analysts view the implied sales expectations required to justify the current valuation as unrealistic given the firm's current forecasts for its cancer business.
The average Wall Street price target sits at $110.44, which is 42% below where the stock currently trades, indicating a wide divergence in opinion among analysts.
Clinical trial resultsDrug approvalNew drug indicationAI-generated analysis
Moderna (MRNA) and Merck announced a landmark breakthrough in August regarding their therapeutic cancer vaccine, intismeran autogene (INT), which combines mRNA technology with Keytruda. Phase 3 study results showed the combination significantly reduced the risk of melanoma recurrence or death by 49% over five years compared to Keytruda alone, with 72% of patients remaining relapse-free versus 49% on Keytruda monotherapy.
The collaboration aims to expand beyond melanoma to treat lung, kidney, and bladder cancers, leveraging the high mutation rates found in these 'hot' tumors. Analysts project that if approved, INT could generate $18 billion to $31 billion in de-risked sales, potentially outstripping Keytruda's current run rate in early-stage cancers. Moderna stock surged over 200% following the initial readout, reflecting high market expectations for this transformative asset.
Despite the excitement, challenges remain regarding regulatory approval timelines, potential pricing hurdles with insurers due to the therapy's high cost, and the need for further data on overall survival and efficacy in 'cold' tumors. While some analysts caution that shares may have run ahead of fundamentals or that the drug could be a 'one-trick pony' limited to melanoma, the success represents a major validation of mRNA technology in oncology after decades of prior failures.
Merck will handle global commercialization and booking of sales, while Moderna receives a share of profits. Analysts forecast INT sales peaking at roughly $2.5 billion for Moderna by 2030, making it the company's second-largest product behind its flu shot. The upcoming presentation of full data at the European Society of Medical Oncology meeting in October is expected to be a critical juncture for determining the drug's broad applicability and long-term value.
π Moderna's cancer vaccine cuts melanoma recurrence risk by 49% over five years.
π° Therapy could generate $18B-$31B in sales, peaking at $2.53B for Moderna in 2030.
π Stock surged 200% and broke out with a relative strength rating of 99.
β οΈ Insurers may balk at high price as additive treatment to existing expensive drugs.
π Analysts warn shares are overextended and drug might be effective only in melanoma.
π Moderna and Merck reported Phase 3 data showing their cancer vaccine reduced melanoma recurrence risk by 49% over five years compared to Keytruda alone.
π° Analysts estimate the therapy could generate $18 billion to $31 billion in total sales, potentially exceeding Keytruda's annualized run rate in early-stage cancers.
π Moderna stock surged more than 200% following the August readout, breaking out of a technical base with a relative strength rating of 99.
π¬ The vaccine targets up to 34 neoantigens specific to a patient's cancer, training the immune system to attack remaining cells after surgery.
β οΈ Insurers may balk at the high price tag, as the therapy is an additive treatment rather than a replacement for existing expensive drugs like Keytruda.
π Full data presentation is scheduled for the European Society of Medical Oncology meeting in Madrid on October 24 to confirm Phase 2 results.
π The companies plan to expand testing to lung, bladder, and head-and-neck cancers, though success rates vary by tumor type and mutation levels.
πΈ Analysts project Moderna's share of sales will peak at roughly $2.53 billion in 2030, making INT its second-biggest product after the flu shot.
π Some analysts warn that shares may be overextended and caution that the drug could prove effective only in melanoma ('one-trick pony').
𧬠The success of INT dispels years of skepticism surrounding mRNA cancer vaccines, marking a potential renaissance for the technology post-pandemic.
π€ Merck will commercialize the drug globally while Moderna receives a share of profits based on sales volume.
π Further data on overall survival and efficacy in 'cold' tumors like pancreatic or colorectal cancer is needed to broaden the drug's indications.
π Citi analyst Geoff Meacham downgraded Moderna to a sell rating, citing concerns that the stock has outrun its fundamentals.
π§ͺ The therapy does not add new side effects beyond those associated with Keytruda, such as fatigue and joint pain.
π₯ Healthcare payers face budget constraints from high-cost therapies, potentially limiting access despite proven efficacy in reducing recurrence.
Bullish Signals
Phase 3 data shows 49% melanoma recurrence risk reduction vs Keytruda.
Risk Factors
Insurers may balk at high therapy price tag.
Bullish Signals
Moderna and Merck achieved a landmark win with Phase 3 data showing their cancer vaccine reduced melanoma recurrence risk by 49% over five years compared to Keytruda alone.
The therapy targets up to 34 neoantigens specific to a patient's cancer, offering a personalized approach that trains the immune system to prevent relapse after surgery.
Analysts project the vaccine could generate $18 billion to $31 billion in total sales, potentially outstripping Keytruda's current annualized run rate in early-stage cancers.
Moderna stock surged over 200% following the initial readout, reflecting strong market confidence and a technical breakout with a perfect IBD Relative Strength Rating of 99.
The success validates mRNA technology for oncology after decades of failures, potentially launching a renaissance for the platform beyond just viral vaccines.
Analysts forecast Moderna's share of sales will peak at roughly $2.53 billion in 2030, establishing INT as the company's second-largest product behind the flu shot.
The vaccine is designed to work with 'hot' tumors like melanoma which have high mutation rates, making them ideal candidates for immune system activation.
Merck and Moderna plan to expand testing to nine other ongoing or planned studies covering lung, bladder, and head-and-neck cancers.
Risk Factors
Insurers are likely to balk at the high price tag of a million-dollar therapy, creating potential access hurdles despite proven efficacy in reducing recurrence.
Some analysts caution that shares have run ahead of fundamentals and warn the drug could be a 'one-trick pony' limited primarily to melanoma.
Citi analyst Geoff Meacham downgraded Moderna to a sell rating, citing risks that the cancer vaccine might not live up to the hype surrounding it.
The therapy is an additive treatment rather than a replacement for existing expensive drugs like Keytruda, complicating payer budget negotiations.
Success rates are projected to be lower in 'cold' tumors like pancreatic or colorectal cancer, limiting the broad applicability of the platform.
There is uncertainty regarding overall survival data, which analysts say will be key to confirming a 'home run' for the stock.
Regulatory approval timelines are not yet confirmed, and full data presentation at the upcoming conference could reveal nuances that temper current enthusiasm.
Moderna (MRNA) shares fell nearly 6% in premarket trading after Citigroup downgraded the biotechnology company from 'Hold' to 'Sell' and raised its price target to $80 from $60. The downgrade stems from concerns that Moderna's current valuation is difficult to justify given its lower expected revenue and earnings compared to peers like Regeneron, despite having a similar market capitalization of roughly $80 billion.
Citi analyst Geoff Meacham noted that even assuming a 100% probability of success for Moderna's lead oncology program, intismeran autogene, the stock would only support a price target of approximately $100. To justify the current trading level near $203, the firm estimates Moderna would need to generate about $26 billion in annual oncology sales, which is roughly seven times its current model projections.
The aggressive valuation reflects high expectations for intismeran's performance following positive late-stage trial results released on August 19. These trials showed the personalized cancer vaccine combined with Merck's Keytruda met goals in over 1,100 patients with advanced melanoma, driving a rally that saw shares rise from around $62 to an intraday high of $208 before the recent decline.
π Citi downgrades Moderna to 'Sell' with an $80 price target.
π° Analysts value Moderna at ~$100 despite intismeran's 100% success potential.
π Shares rallied 223% since August following positive intismeran trial results.
β οΈ Citi requires $26B annual oncology sales to justify a $200 share price.
π Mixed analyst sentiment with 15 of 24 ratings as 'Buy'.
π Moderna stock dropped nearly 6% in premarket trading following Citigroup's downgrade from 'Hold' to 'Sell' and a price target increase to $80.
π° Citi analyst Geoff Meacham stated that even with a 100% success rate for the intismeran oncology program, the stock supports only a ~$100 valuation.
π The company's roughly $80 billion market cap is comparable to Regeneron despite Moderna having significantly lower expected revenue and earnings.
π Shares have rallied 223% since August 19 after positive late-stage trial results for the personalized cancer vaccine candidate intismeran autogene.
π¬ The lead oncology program combined with Merck's Keytruda met trial goals in more than 1,100 patients with higher-risk or advanced melanoma.
β οΈ Citi estimates Moderna would need to generate about $26 billion in annual oncology sales to justify a share price near $200.
π The current valuation reflects aggressive sales expectations and probability-of-success assumptions that the bank considers unrealistic.
π₯ While melanoma is viewed as a favorable setting for demonstrating treatment potential, other applications like renal and lung cancers present different biological challenges.
π Citigroup's new $80 price target implies roughly 61% downside from Tuesday's closing price of $203.46.
π₯ Analyst sentiment remains mixed with 15 of 24 analysts rating the stock as a buy, while three hold underperform ratings.
Bullish Signals
Shares rallied 223% after intismeran autogene late-stage trial results.
Oncology program with Merck's Keytruda met goals in 1,100+ patients.
Risk Factors
Citi downgraded stock to 'Sell' with $80 target due to high valuation.
Oncology success unlikely to support current price per Citi estimates.
Needs $26B annual oncology sales to justify ~$200 share price.
Bullish Signals
Moderna shares have rallied 223% since August 19 following positive late-stage trial results for its personalized cancer vaccine candidate intismeran autogene.
The lead oncology program, when combined with Merck's Keytruda, met trial goals in more than 1,100 patients with higher-risk or advanced melanoma.
Risk Factors
Citigroup downgraded Moderna from 'Hold' to 'Sell' and raised its price target to $80, citing concerns that the current valuation is difficult to justify.
Citi estimates that even assigning a 100% probability of success to intismeran oncology programs would only support a price target of about $100 per share.
The firm stated that Moderna would need to generate about $26 billion in annual oncology sales to justify a share price near $200, which is almost seven times its current model.
Moderna Inc. (MRNA) is approaching a critical oncology milestone with Phase 3 melanoma data for its intismeran autogene candidate scheduled for presentation at the ESMO Congress on October 24, 2026. The company has received acceptance for three abstracts, with the central presentation focusing on a study of intismeran combined with pembrolizumab versus pembrolizumab alone in resected stage IIB-IV melanoma patients.
Following the recent quarter ended June 30, 2026, Moderna reported a sharp sequential contraction in revenue, falling to USD 0.1 billion from USD 0.4 billion in the prior quarter. The company also posted a GAAP net loss of USD 0.8 billion and an EPS of minus USD 1.97, highlighting its continued dependence on successful product launches and pipeline progress rather than current earnings power.
Wall Street analysts are closely watching the upcoming data for specific efficacy metrics. UBS reiterated a Neutral rating with a USD 150.00 price target, noting the market expects a hazard ratio of 0.65 or better (equivalent to a 35 percent risk reduction). Conversely, Bernstein SocGen Group maintains a Market Perform rating but has set a significantly lower USD 45.00 price target, underscoring the high valuation sensitivity to the melanoma program's outcome.
Moderna stock was trading at EUR 172.26 on September 29, 2026, reflecting a slight decline of 0.77 percent against the prior close. The company remains listed on Nasdaq with a market capitalization of USD 78.3 billion and a 52-week trading range spanning from USD 22.28 to USD 202.67, as investors await the investor webcast scheduled for October 24 at 7:00 p.m. CEST.
π Moderna presents Phase 3 melanoma data for intismeran on October 24, 2026.
π Study evaluates intismeran plus pembrolizumab versus pembrolizumab alone in stage IIB-IV patients.
π Q2 revenue fell sharply to USD 0.1 billion from USD 0.4 billion in Q1.
πΈ GAAP net loss reached USD 0.8 billion with EPS of minus USD 1.97.
π Moderna is set to present Phase 3 melanoma data for intismeran autogene at the ESMO Congress on October 24, 2026.
π The central study evaluates intismeran combined with pembrolizumab versus pembrolizumab alone in resected stage IIB-IV melanoma patients.
π Q2 revenue fell sharply to USD 0.1 billion from USD 0.4 billion in Q1, representing a significant sequential contraction.
πΈ The company reported a GAAP net loss of USD 0.8 billion and an EPS of minus USD 1.97 for the quarter ended June 30, 2026.
π― UBS reiterated a Neutral rating with a USD 150.00 price target, expecting a hazard ratio of 0.65 or better for approval.
π Bernstein SocGen Group maintains a Market Perform rating but set a lower USD 45.00 price target ahead of the data.
π Moderna stock traded at EUR 172.26 on September 29, 2026, down 0.77 percent versus the prior close.
π° The company holds a market capitalization of USD 78.3 billion with a 52-week range between USD 22.28 and USD 202.67.
π€ An investor webcast is scheduled for October 24 at 7:00 p.m. CEST to discuss the upcoming clinical readout.
Bullish Signals
Intismeran abstracts accepted for ESMO Congress presentation.
Hosting investor webcast for melanoma Phase 3 update.
Risk Factors
Q2 revenue dropped sharply to USD 0.1 billion from USD 0.4 billion.
Reported substantial GAAP net loss of USD 0.8 billion and EPS minus USD 1.97.
Analysts demand hazard ratio of 0.65, creating high pressure on upcoming data.
Bullish Signals
Moderna has secured acceptance for three abstracts regarding its intismeran autogene candidate for presentation at the prestigious ESMO Congress.
The company is hosting a dedicated investor webcast on October 24 to provide a clear update on the pivotal melanoma Phase 3 study results.
Risk Factors
Q2 revenue dropped sharply to USD 0.1 billion from USD 0.4 billion in the previous quarter, indicating significant sequential contraction.
The company reported a substantial GAAP net loss of USD 0.8 billion and an EPS of minus USD 1.97 for the quarter ended June 30, 2026.
Analysts are demanding a hazard ratio of 0.65 or better (35 percent risk reduction) to justify current valuations, creating high pressure on the upcoming data.
Moderna Inc. (MRNA) shares closed at USD 198.88 on September 25, 2026, representing a gain of 2.08 percent from the prior session. The stock price reflects ongoing investor interest in the biotechnology firm's pipeline developments and recent corporate announcements regarding its investigational therapies.
Moderna announced that three abstracts concerning intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. The congress is scheduled to take place from October 23 through October 27.
The core of the presentation program includes Phase 3 data from the INTerpath-001 study, which evaluates intismeran autogene plus pembrolizumab versus pembrolizumab alone in patients with resected stage IIB-IV melanoma. Additionally, the company will present Phase I data for a pancreatic cancer study and Phase 3 results for high-risk stage I non-small cell lung cancer.
Moderna plans to host an investor webcast on October 24 at 7:00 p.m. CEST (1:00 p.m. EDT) to discuss these findings, with a replay available for at least 30 days. ACCESS Newswire identified Moderna and Merck as joint developers of intismeran autogene.
π Moderna stock rose 2.08% to close at USD 198.88 on September 25, 2026.
π¬ Three abstracts for intismeran autogene accepted for ESMO Congress 2026 presentation in Madrid.
π Phase 3 data from INTerpath-001 study comparing intismeran autogene plus pembrolizumab vs pembrolizumab alone.
𧬠Additional presentations include Phase I pancreatic cancer data and Phase 3 high-risk stage I NSCLC results.
ποΈ Investor webcast scheduled for October 24 at 7:00 p.m. CEST to discuss upcoming scientific data.
π Moderna stock traded up 2.08 percent to close at USD 198.88 on September 25, 2026.
π¬ Three abstracts regarding intismeran autogene were accepted for presentation at ESMO Congress 2026 in Madrid.
π The company will present Phase 3 data from the INTerpath-001 study comparing intismeran autogene plus pembrolizumab against pembrolizumab alone in resected stage IIB-IV melanoma.
𧬠Additional presentations include Phase I data for a pancreatic cancer study and Phase 3 results for high-risk stage I non-small cell lung cancer.
ποΈ Moderna will host an investor webcast on October 24 at 7:00 p.m. CEST to discuss the upcoming scientific data.
π€ ACCESS Newswire confirms that Moderna and Merck are joint developers of intismeran autogene.
Bullish Signals
Stock gained 2.08% to close at USD 198.88 on Sept 25, 2026.
Secured acceptance for three intismeran autogene therapy abstracts at ESMO Congress 2026.
Bullish Signals
Moderna stock gained 2.08 percent, closing at USD 198.88 on September 25, 2026.
The company secured acceptance for three significant abstracts regarding its intismeran autogene therapy at the prestigious ESMO Congress 2026.
Moderna Inc. shares opened higher on September 25, 2026, following a significant 6.98 percent gain that pushed the stock price to USD 194.82 at the close of the previous session. The biotechnology company's performance was robust, with intraday trading reaching a new four-year peak of USD 195.71, significantly outpacing the broader Nasdaq Composite which rose only marginally by 0.01 percent to finish at 26,939.37.
Trading volume for Moderna stood at approximately 10.3 million shares during the session, with the stock fluctuating between a low of USD 180.39 and its intraday high. The substantial price appreciation reflects strong investor sentiment driven by specific corporate developments rather than general market trends.
The primary catalyst for this bullish move was reported discussions regarding potential investment opportunities and cooperation in the Middle East region. Reports from financial outlets highlighted talks concerning advanced pharmaceutical industries, specifically mentioning potential engagement with entities in the United Arab Emirates on September 24, 2026.
π Moderna stock surged 6.98% to close at USD 194.82 on Sept 24, 2026.
π Shares hit a new four-year high of USD 195.71 during the session.
Moderna Inc. reported strong second-quarter 2026 financial results, generating revenue of USD 145.00 million against a consensus estimate of USD 102.93 million, representing a significant beat. The company also posted earnings per share (EPS) of USD -1.97, which exceeded the estimated loss of USD -2.03 by USD 0.06. Despite remaining in a loss-making position, the revenue growth indicates improving commercial performance and validates the company's pipeline valuation.
The stock was trading at USD 182.11 on September 23, 2026, which is below its 52-week high but reflects a substantial discount to analyst price targets. MarketBeat reports an average price target of USD 76.72 with a Hold consensus rating, creating a valuation debate where the current market price sits nearly 58% above the average target. This discrepancy positions the upcoming oncology data presentation as a critical test for the company's narrative.
Moderna is preparing to present Phase 3 data for its melanoma candidate, intismeran (autogene), at the ESMO Congress on October 24, 2026. The presentation will cover updates on personalized therapies for pancreatic and lung cancer as well, providing near-term evidence points for the oncology pipeline. An investor webcast is scheduled for the same date to discuss these developments.
π Moderna beat Q2 revenue estimates with USD 145M vs USD 103M consensus.
π° EPS of USD -1.97 beat negative consensus estimate of USD -2.03.
π Stock at USD 182 trades steep discount to USD 76 analyst target.
π¬ Phase 3 melanoma data for intismeran presented at ESMO October 24, 2026.
ποΈ Oncology pipeline investor webcast scheduled for October 24, 2026 at 1:00 p.m. EDT.
π Moderna beat Q2 2026 revenue estimates significantly with USD 145.00 million reported versus a consensus of USD 102.93 million.
π° The company posted an EPS of USD -1.97, beating the negative consensus estimate of USD -2.03 by USD 0.06.
π Stock price of USD 182.11 trades at a steep discount to the average analyst price target of USD 76.72 reported by MarketBeat.
π¬ Phase 3 data for melanoma candidate intismeran is scheduled for presentation at the ESMO Congress on October 24, 2026.
ποΈ An investor webcast regarding oncology pipeline updates is set for October 24, 2026, at 1:00 p.m. EDT.
𧬠The company will present three ESMO abstracts covering melanoma and personalized therapies for pancreatic and lung cancer.
Bullish Signals
Q2 2026 revenue hit USD 145M, beating USD 102.93M consensus.
EPS beat estimates with a loss of USD -1.97 vs -2.03.
Risk Factors
Stock trades at $182.11, nearly 58% above analyst target.
Company remains loss-making with quarterly EPS of -$1.97.
Bullish Signals
Moderna generated USD 145.00 million in Q2 2026 revenue, significantly exceeding the USD 102.93 million consensus estimate.
The company beat EPS estimates with a loss of USD -1.97 compared to the expected loss of USD -2.03.
Risk Factors
The stock trades at USD 182.11, which is nearly 58% above the average analyst price target of USD 76.72 held by MarketBeat.
Despite revenue growth, the company remains loss-making with quarterly EPS of USD -1.97.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)